gadobenic acid (gadobenate dimeglumine)

used in MR imaging of liver

Also Known As:

gadobenate dimeglumine; 3,6,9-triaza-12-oxa-3,6,9-tricarboxymethylene-10-carboxy-13-phenyltridecanoic acid, gadolinium; B 19036; B-19036; Gd(BOPTA)2; Gd-BOPTA; MultiHance; gadobenic acid, dimeglumine salt; gadolinium-BOPTA-Dimeg; gadolinium-benzyloxypropionyl tetraacetate

Networked: 341 relevant articles (27 outcomes, 57 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kirchin, Miles A: 24 articles (12/2015 - 03/2002)
2.	Pirovano, Gianpaolo: 12 articles (09/2015 - 03/2002)
3.	Catalano, Carlo: 12 articles (12/2014 - 10/2005)
4.	Kirchin, M A: 10 articles (09/2015 - 01/2000)
5.	Passariello, Roberto: 10 articles (02/2012 - 10/2005)
6.	Spinazzi, Alberto: 8 articles (09/2015 - 12/2002)
7.	Essig, Marco: 8 articles (06/2011 - 01/2004)
8.	Schneider, Günther: 8 articles (02/2011 - 12/2002)
9.	Colosimo, C: 7 articles (12/2019 - 02/2001)
10.	Grazioli, Luigi: 7 articles (10/2019 - 05/2003)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2002 - "Corresponding results with ICP-AES showed significantly greater uptake of Gd-BOPTA in tumor samples than that in peritumoral tissue and normal brain 5 minutes after administration. " 12/01/2015 - "Low-dose gadobenate dimeglumine-enhanced MRI is effective for the differential diagnosis of malignant renal tumors." 12/01/2019 - "The efficacy of gadobenate dimeglumine-enhanced MR imaging was evaluated prospectively by 3 blinded, unaffiliated readers in terms of the accuracy of combined pre- and postcontrast images relative to precontrast images alone for differentiation of tumor from non-neoplastic disease and the correct diagnosis of specific disease. " 05/01/2014 - "The aim of this study was to compare the diagnostic accuracy of the late phase of CEUS and the hepatobiliary phase of CE-MR with Gd-BOPTA in the characterization of focal liver lesions in terms of benignity and malignancy. " 11/01/1999 - "MultiHance in the assessment of intracranial tumors: results of phase II clinical studies."
2.	Brain Neoplasms (Brain Tumor) 11/01/1999 - "To assess preliminarily the efficacy of 0.1 and 0.2 mmol/kg doses of MultiHance for contrast-enhanced magnetic resonance imaging of brain tumors. " 01/01/2021 - "This prospective study was to explore the clinical value of contrast-enhanced T2 FLAIR in imaging brain metastases using half-dose gadobenate dimeglumine. " 11/01/2006 - "In this article we review the unique MR imaging properties of MultiHance for the assessment of brain tumors and other cerebral pathologies, and give practical information on how best to optimize MR sequence parameters to achieve the optimal contrast between normal CNS tissue and lesion." 03/01/2006 - "A total of 28 patients with intraaxial brain tumors underwent conventional MR imaging (T2- and T1-weighted sequences after gadobenate dimeglumine injection), diffusion imaging and T2*-weighted echo-planar perfusion imaging. " 06/01/2004 - "MultiHance in brain tumor imaging."
3.	Neoplasm Metastasis (Metastasis) 01/01/2004 - "The Gd-BOPTA during both dynamic and delayed phases provides valuable information for the characterization of focal liver lesions, and furthermore, Gd-BOPTA-enhanced DPI contributed to the improved detection of liver metastasis compared to precontrast and early dynamic imaging." 10/01/2019 - "Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI." 05/01/2015 - "The purpose of this prospective study was to test the feasibility for using one of these agents, gadobenate dimeglumine, to detect liver metastases in dogs. " 05/01/2015 - "Feasibility for detecting liver metastases in dogs using gadobenate dimeglumine-enhanced magnetic resonance imaging." 03/01/2010 - "To assess the diagnostic performance of gadobenate dimeglumine-enhanced 3D gradient echo (3D-GRE) magnetic resonance imaging (MRI) for the detection of hepatic hypovascular metastases. "
4.	Breast Neoplasms (Breast Cancer) 06/01/2005 - "Gadobenate dimeglumine is effective for MR imaging evaluation of breast vessels at doses as low as 0.05 mmol/kg. One-sided increased vascularity is an MR imaging finding frequently associated with ipsilateral invasive breast cancer." 07/07/2015 - "[Controlled study of gadobenate dimeglumine versus gadopentetate in breast tumor MR dynamic enhancement scanning]." 02/01/2011 - "Readers 1, 2, and 3 reported significantly superior diagnostic performance (sensitivity, specificity, and accuracy) for breast cancer detection with gadobenate dimeglumine (91.1%, 94.5%, 95.2% vs 81.2%, 82.6%, 84.6%; 99.0%, 98.2%, 96.9% vs 97.8%, 96.9%, 93.8%; 98.2%, 97.8%, 96.7% vs 96.1%, 95.4%, 92.8%, respectively; P ≤ .0094) and significantly superior PPV (91.1%, 85.2%, 77.2% vs 80.7%, 75.5%, 60.9%, respectively; P ≤ .0002) and NPV (99.0%, 99.4%, 99.4% vs 97.8%, 98.0%, 98.1%, respectively; P ≤ .0003). " 07/01/2009 - "Two hundred thirty-eight women with dense breast parenchyma who were suspicious for breast cancer or inconclusive for the presence of breast lesions based on clinical examination, ultrasound or x-ray mammography, and who underwent breast MRI at 1.5 T before and after administration of 0.1 mmol/kg gadobenate dimeglumine were evaluated. " 06/01/2007 - "To prospectively evaluate accuracy of gadobenate dimeglumine-enhanced magnetic resonance (MR) mammography for depiction of synchronous contralateral breast cancer in patients with newly diagnosed unilateral breast cancer or high-risk lesions, with histologic analysis or follow-up as reference. "
5.	Peripheral Arterial Occlusive Disease 1 11/01/2007 - "Improved diagnostic performance and reproducibility are achievable with gadobenate dimeglumine-enhanced MR angiography in patients with peripheral arterial occlusive disease." 11/01/2007 - "The purpose of this study was to compare gadobenate dimeglumine-enhanced MR angiography and unenhanced time-of-flight MR angiography for the detection of significant peripheral arterial occlusive disease using digital subtraction angiography as our reference standard. " 05/01/2011 - "A total of 35 patients with symptomatic peripheral arterial occlusive disease (PAOD) underwent FP MRA (repetition time [TR]/echo time [TE]/flip angle [FA]/acquisition time [TA] = 3.5/1.2/30°/14s) at 1.5T after intravenous injection of 10 mL of gadobenate dimeglumine. " 06/01/2010 - "Higher-quality vessel visualization, greater contrast enhancement, fewer technical failures, and improved diagnostic performance are obtained with gadobenate dimeglumine, relative to gadopentetate dimeglumine, when compared intraindividually at 0.1-mmol/kg doses in patients undergoing contrast-enhanced MR angiography for suspected peripheral arterial occlusive disease." 10/01/2013 - "To prospectively compare single dose gadobenate dimeglumine with double dose gadopentetate dimeglumine for CE-MRA in patients with peripheral arterial occlusive disease (PAOD) using an intra-individual crossover study design in which all patients received both contrast agents in otherwise identical CE-MRA examinations. "

Related Drugs and Biologics

1.	gadobenic acid (gadobenate dimeglumine)
2.	Contrast Media
3.	Gadolinium DTPA (Magnevist)
4.	Gadolinium
5.	gadodiamide (Omniscan)
6.	gadolinium ethoxybenzyl DTPA
7.	gadobutrol
8.	gadoterate meglumine
9.	N,N'- bis(pyridoxal- 5- phosphate)ethylenediamine- N,N'- diacetic acid (mangafodipir)
10.	Phosphates (Orthophosphate)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Liver Transplantation
3.	Microbubbles
4.	Renal Replacement Therapy (Therapies, Renal Replacement)
5.	Injections